Solventum (SOLV) jumped 11.1% over the past five sessions, closing at $90.38 on November 6, 2026, after the company reported third-quarter earnings that, while showing a revenue decline, beat on adjusted EPS and guided through an ERP-related disruption. The stock now sits just 2.2% below its 52-week high of $92.44, with the daily trend aligned with the weekly uptrend and the balance of evidence leaning positive for the next 2–6 weeks. The stance has changed from neutral to bullish, with medium conviction.
Why it matters
Solventum reported its quarterly 10-Q and 8-K on November 5, 2026. Revenue came in at $1.95 billion, down 7% year-over-year, but the decline was largely due to a 630 basis point impact from prior quarter advance orders ahead of its ERP cutover. Organically, revenue fell only 2.8%. GAAP diluted EPS was -$0.07, but adjusted diluted EPS fell just 3.6% to $1.45, a much smaller decline than the headline numbers suggested. The market clearly focused on the adjusted figure and the ERP explanation, as the stock rose 3.7% on the day and continued higher into the close.
What was already priced in? Before the earnings release, SOLV had been lagging its sector. Over the past 50 days, the stock was up 7.3% relative to the S&P 500, but down 3.5% relative to the Health Care Select Sector SPDR Fund (XLV). That relative weakness suggested investors were cautious about the ERP disruption and the revenue decline. The earnings report removed some of that caution, and the stock's 11.1% five-day gain reflects a repricing of those concerns.
How much of the move was the stock itself? Over the past five days, SOLV rose 11.1% while the S&P 500 fell 2.7% and XLV was roughly flat. The stock's excess return over its sector was 11.2 percentage points. This was a company-specific move, driven by the earnings report and the market's interpretation of it, not a broad market or sector rally.
The debate around SOLV is whether the ERP disruption is a one-time event or a sign of deeper operational issues. The bulls point to the adjusted EPS of $1.45, which beat expectations, and the fact that organic revenue declined only 2.8% despite the advance-order impact. The bears note that revenue is still declining, net income turned negative at -$12 million, and the company faces integration challenges. The analyst consensus is "buy" with a mean target of $94.69, ranging from $71 to $113, and the stock trades 4.6% below that mean. The wide spread suggests genuine disagreement about the company's trajectory.
What the evidence says
The long-term trend is intact. SOLV trades at $90.38, above its 40-week average and its 200-day average of $78.55. The stock is up 27.3% over six months and 14.1% year-to-date, while the S&P 500 is up 7.8% year-to-date. The thesis—that Solventum can grow earnings as it integrates and moves past the ERP disruption—remains viable. The stock is in an uptrend phase, with price above its 50-day average of $87.73 and its 10-week average.
For the next 2–6 weeks, the balance of evidence leans positive. The daily trend runs with the weekly uptrend, the stock is leading the S&P 500 by 7.3% over 50 days, and the earnings report removed a key overhang. Conviction is medium, not high, because the stock still lags XLV by 3.5% over 50 days, suggesting the sector is not confirming the move. The strongest case against the bullish reading is that the stock has already rallied 11.1% in five days and now sits just below resistance at $92.44. A failure to break through could lead to a pullback toward $90 or even the 50-day average at $87.73. That risk is real, but it does not tip the balance because the trend is aligned and the earnings catalyst was positive.
Levels that matter
The structure holds above $90.00, a round number that has acted as support. A daily close below $90.00 would be the first crack in the recent strength, but the trend would only end on a weekly close below the 50-day average at $87.73. That level is the line in the sand: as long as the stock stays above it, the uptrend is intact.
The breakout level is a daily close above $92.44, the 52-week high, on volume above the 20-day average. From there, the first target is $100.00, a round number, which gives a reward-to-risk of 2.3 to 1 against a stop at $89.22 (based on $90.00 minus a quarter of the ATR). The second target is $110.00, a round number, with a reward-to-risk of 5.5 to 1. The math meets the 3-to-1 threshold for a breakout worth taking. If the stock fails to break out and instead falls below $87.73, the picture changes.
What would change the picture
The picture would change on a weekly close below $87.73, the 50-day average. That would signal that the uptrend has broken and the recent rally was a false start. The only non-price fact that would change the picture is a negative revision to the company's guidance or a significant operational setback, such as a further ERP-related disruption or a larger-than-expected revenue decline in the next quarter.
What to watch
- Next earnings: The next report is expected in early February 2027. The key number will be organic revenue growth, which should show whether the ERP disruption is truly behind the company.
- Sector events: Watch for any healthcare policy news or changes in medical device regulation that could affect the sector. XLV's relative performance versus SOLV will also matter—if the sector starts to lag, it could drag SOLV down despite its own strength.
- Valuation: The stock trades 4.6% below the analyst mean target of $94.69, but the range is wide ($71–$113). A move above the mean target would suggest the market is pricing in a full recovery, while a move below the low end would indicate serious doubts.